跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,594 条关于
“Aumolertinib Mesylate Tablets”
全部
12,594
临床试验
10,440
药物
1,204
机构
83
资讯
867
8个月前
Hansoh Pharmaceutical's Aumolertinib Receives EU Approval for Advanced NSCLC Treatment
去年
Aumolertinib Shows Significant PFS Benefit in EGFR-Mutated Stage III NSCLC
2年前
Aumolertinib Significantly Improves PFS in Stage III EGFR+ NSCLC After Chemoradiotherapy
去年
Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC
9个月前
Glenmark Secures Global Rights to Third-Generation EGFR-TKI Aumolertinib for Lung Cancer Treatment
去年
Hansoh Pharma's Aumolertinib Plus Chemotherapy Shows Positive Phase III Results in EGFR-Mutated NSCLC
去年
Aumolertinib Plus Anlotinib Shows Promise for Untreated EGFR-Mutant NSCLC with CNS Metastases
去年
China's NMPA Accepts NDAs for Lung and Liver Cancer Therapies
去年
Foresee Pharmaceuticals Seeks FDA Approval for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer
去年
Glenmark Launches First Generic Eribulin Mesylate Injection in $66.3 Million Market
第 1 页，共 87 页
上一页
下一页
